

Initial characterisation of commercially available ELISA tests and the immune response of the clinically correlated SARS-CoV-2 biobank “SERO-BL-COVID-19” collected during the pandemic onset in Switzerland

Hans-Michael Kaltenbach,^{a,1} Fabian Rudolf,^{a,b,1,*} Janina Linnik^a, Julia Deichmann^a, Therese Ruf^c, Raffaele Altamura^d, Edo Kapetanovic^d, Derek Mason^d, Bastian Wagner^d, Thomas Goetz^e, Lukas Mundorff^e, Karin Stoll-Rudin^c, Christina Krebs^c, Tanja Renz^e, Thomas Hochueli^f, Sergio Haymoz^f, Markus Hosch^g, Nadine Périat^g, Michèle Richert^g, Sergio Sesia^{h,i}, Daniel Paris^c, Carlos Beat Quinto^{c,g,j,k,l}, Nicole M. Probst-Hensch^c, Christoph Niederhauser^{n,o}, Sai Reddy^d, Beatrice Nickel^c, Miodrag Savic^{g,l,m,*}

^aD-BSSE ETH Zürich & Swiss Institute of Bioinformatics, Mattenstrasse 26, 4056 Basel, Switzerland

^bAssociated Member Cantonal Crisis Staff Basel-Landschaft, 4410 Liestal

^cSwiss Tropical and Public Health Institute, Socinstrasse 57, 4051 Basel

^dD-BSSE ETH Zürich, Mattenstrasse 26, 4056 Basel

^eCanton Basel-Landschaft Medical Association, 4132 Muttentz

^fOffice for Military Affairs and Civil Protection Canton Basel-Landschaft, 4410 Liestal

^gDepartment of Health, Economics and Health Directorate Canton Basel-Landschaft, 4410 Liestal

^hUniversity of Berne, 3000 Berne

ⁱUniversity Hospital of Berne, 3000 Berne

^jDepartment of Public Health, Health Professions and Medicines, 4000 Basel

^kSwiss Medical Association

^lUniversity of Basel, 4000 Basel

^mUniversity Hospital of Basel, 4000 Basel

ⁿInterregional Blood Transfusion SRC, 3000 Bern

^oInstitute for Infectious Diseases, University of Bern, 3000 Bern

Abstract

Background To accurately measure seroprevalance in the population, both the expected immune response as well as the assay performances have to be well characterised. Here, we describe the collection and initial characterisation of a blood and saliva biobank obtained after the initial peak of the SARS-CoV-2 pandemic in Switzerland.

Methods Two laboratory ELISAs measuring IgA & IgG (Euroimmun), and IgM & IgG (Epitope Diagnostics) were used to characterise the biobank collected from 349 re- and convalescent patients from the canton of Basel-Landschaft.

Findings The antibody response in terms of recognized epitopes is diverse, especially in oligosymptomatic patients, while the average strength of the antibody response of the population does correlate with the severity of the disease at each time point.

Interpretation The diverse immune response presents a challenge when conducting

*correspondence should be addressed to fabian.rudolf@bsse.ethz.ch or miodrag.savic@usb.ch

¹these authors contributed equally

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

epidemiological studies as the used assays only detect $\sim 90\%$ of the oligosymptomatic cases. This problem cannot be rectified by using more sensitive assay setting as they concomitantly reduce specificity.

Funding Funding was obtained from the "Amt für Gesundheit" of the canton Basel-Landschaft, Switzerland.

Keywords: COVID-19, SARS-CoV-2, Serology, Biobank, Immune response, oligosymptomatic patients, ELISA

1. Introduction

Effective host responses to viral infections, including those to coronaviruses, are driven by adaptive immunity [1]. For endemic or previously emerging coronaviruses, the antibody response has been correlated with protection from re-infection for a varying period of time. In SARS-CoV-2 infections, most studies on antibody kinetics are based on severe or hospitalized patients, even though subclinical or even oligosymptomatic patients represent the majority of cases. Less severe cases of SARS-CoV-2 (as well as other endemic CoVs) are associated with lower antibody responses, and therefore pose a challenge for accurate detection using serological assays.

However, one of the most important correlates of immunological protection is the presence of neutralizing antibodies, which is preferably measured by using functional assays with replication competent virus [2]. For COVID-19 patients, such assays are time consuming and must be conducted in Biosafety Level 3 facilities, which renders them infeasible for wide-scale testing. Some alternative functional assays are based on pseudotyped or chimeric viral particles [3], but these reagents are neither trivial to produce nor do they scale to large sample sizes. The most feasible alternative assays are therefore binding assays, such as enzyme-linked immunosorbent assays (ELISA), and preferably report on the quantity of antibodies binding to neutralizing epitopes such as the receptor binding domain (RBD) of the spike protein [4].

Current clinically approved ELISA tests either bind to the nucleocapsid (NCP) protein or (part of) the spike protein (which includes the RBD). Both of these proteins, but especially the NCP, are known to generate a strong host immune response in other beta-coronaviruses [5, 6]. In contrast, nearly all neutralising antibodies against SARS-CoV-2 discovered to date bind to the small RBD portion of the spike protein [7, 8], and currently available commercial assays indeed insufficiently predict neutralisation [2]. The

26 presence and characterization of antibody responses in COVID-19 patients by serological
27 assays has been described in several reports [9, 10, 11, 12, 13, 14]; a key observation is
28 that across many patients, antibodies are detected at ~ 10 days post-onset of symptoms.

29 The performance of assays is characterized by their sensitivity and specificity [15].
30 To-date, most commercial ELISA performance validations were obtained from biobanks
31 relying on hospitalised patients; this positive patient cohort will likely have higher anti-
32 body levels than milder, non-hospitalized patients [16]. This is also observed for SARS-
33 CoV-2 infections [17]. It is thus unclear if the available tests are sufficiently sensitive to
34 also detect oligosymptomatic cases.

35 Here, we describe the collection and initial analysis of a blood biobank representa-
36 tive for the observed COVID-19 symptomatic range in the population of Switzerland.
37 The positive cohort in this biobank consists of 341 samples obtained from participants
38 determined to have SARS-CoV-2 (PCR-positive test) in various symptomatic and post-
39 symptomatic stages. The negative cohorts include 115 samples obtained from PCR-
40 negative tested participants, and 150 samples of blood donors from the 2016/17 flu
41 season. The distribution in age and disease severity in this biobank is similar to that
42 reported for other areas in Western Europe. For each sample, we measured the antibody
43 response toward the NCP and S1 proteins using the ELISA tests for IgM and IgG from
44 Epitope Diagnostics and IgA and IgG from Euroimmun, and characterized the perfor-
45 mance of these assays. The specificity of both the Euroimmun IgG and the Epitope
46 Diagnostics IgM assays was close to 100%, while the other two tests showed specificities
47 of $\sim 96\%$ and lower. The sensitivity of the IgA and IgG tests was only sufficient to detect
48 $\sim 90\%$ of the cases, while the IgM test only detected $\sim 50\%$. Previous studies reported
49 a low and late IgM response, especially in less severe COVID-19 patients [10, 11], which
50 might partially explain the low IgM test sensitivity. Taken together, our data indicates
51 that the immune response in oligosymptomatic patients is diverse and ill captured with
52 the two employed serological assays.

53 **2. Materials & methods**

54 *2.1. Ethics statement*

55 This study is part of the project 'COVID-19 in Baselland Investigation and Validation
56 of Serological Diagnostic Assays and Epidemiological Study of Sars-CoV-2 specific Anti-
57 body Responses (SERO-BL-COVID-19)' approved by the ethics board "Ethikkommission

58 Northwest- und Zentralschweiz (EKNZ)”, Hebelstrasse 53, 4056 Basel representative of
59 Swissethics under the number (2020-00816).

60 Every participant has received a written informed consent at least 24 hours before
61 participating in this study (attached original document in German language). The par-
62 ticipants had to sign the written informed consent and needed to show it in order to be
63 given access to the test facility. The participants could withdraw their participation at
64 any time without stating any reason.

65 *2.2. Collection of samples*

66 *2.2.1. Blood Collection*

67 Venous blood was taken by puncturing a disinfected cubital or similar area using a
68 BD safety-lock system into a vacutainer. In total, 10–12 mL each for EDTA-blood serum
69 was taken. The blood collection was performed by a medical assistant or nurse. After
70 blood collection, the samples were either transferred to the diagnostic lab or directly
71 processed on site in the make-shift laboratory.

72 *2.2.2. Saliva Collection*

73 Saliva was collected non-invasively using the dedicated Salivette tubes (Sarstedt
74 Cat. # 51.1534). In short, the participant delivered saliva into an adsorbent filter, which
75 was then placed by the participant in the Salivette tube. After handover to the medical
76 staff, the saliva was centrifuged on site at 4°C using 1,000× g for 2 min to remove cells
77 and debris. The tube was then rapidly frozen using a salted ice-water bath and stored
78 at −20°C before transporting to the lab on dry ice and storage at −80°C until further
79 use.

80 *2.2.3. Plasma and PBMC isolation and cell cryopreservation*

81 Density gradient separation was used in peripheral blood mononuclear cell (PBMC)
82 isolation. 12 mL of fresh donor blood was received in 3× 4 mL plastic whole blood tubes
83 with spray-coated K₂EDTA BD VacutainerTM (Becton Dickinson, Cat. # 367844). The
84 whole blood was diluted in 1:1 ratio with 12 mL of PBS (w/o Ca²⁺ and Mg²⁺). The
85 total volume of diluted blood (24 mL) was gently and slowly layered on 14 mL of Ficoll
86 LymphoprepTM (STEMCELL, Cat. # 07861). Samples were centrifuged at 400× g 40
87 min, 22°C, no brakes. 14 mL of plasma was transferred in a 15 mL conical tube and
88 stored at 4°C. The layer of mononuclear cells was aspirated and transferred in a 50
89 mL conical tube containing 25 mL of PBS (w/o Ca²⁺ and Mg²⁺). Cells were washed

300× g 8 min, 22°C, with brakes. Washing was repeated with an additional 25 mL of PBS (w/o Ca²⁺ and Mg²⁺). Mononuclear cells were subsequently resuspended in 1 mL of freezing media (heat inactivated FBS supplemented with 10% DMSO) and aliquoted into two 1.5 mL cryogenic tubes (Nalgene System, Thermo Scientific, Cat. # 5000-1020). The cryogenic tubes were put into freezing containers Mr.Frosty™ (Thermo Scientific, Cat. # 5100-0001) and the containers were immediately placed into an −80°C freezer for 24 hrs, and then transferred into a liquid nitrogen tank.

2.2.4. Point of care validation

To perform the point of care test (POCT) validation, a capillary blood sample was taken from each subject by puncturing the end of a finger and taking the blood with a micro pipette. Immediately after collecting, the blood was put in the lateral flow chamber of the POCT and after 15 minutes the result was visually scored as positive or negative by the medical assistant. Additionally, the tests were imaged using a Nikon D5000 camera.

2.2.5. Blood donor cohort

Samples from nonremunerated blood donors originate from the Swiss cantons of Thurgau, Basel, Bern, Waadt and Geneva, and were taken during the pre-pandemic period 16th and 17th December 2016. These samples were frozen as EDTA plasmas on microtiterplates for −20°C.

2.3. ELISA analysis

The following four commercially available immunoassays were characterized in the study: the Anti-SARS-CoV-2-ELISA-IgA (Euroimmun AG, Lübeck, # EI 2606-9601 A), the Anti-SARS-CoV-2-ELISA-IgAG (Euroimmun AG, Lübeck, # EI 2606-9601 G), the EDI Novel Coronavirus COVID-19 IgM ELISA kit (Epitope Diagnostics, Inc., # KT-1033) and the EDI Novel Coronavirus COVID-19 IgG ELISA kit (Epitope Diagnostics, Inc., # KT-1032). All ELISA kits were CE and IVD labeled.

To enable a quantitative comparison between ELISA experiments, we calculated fold changes in OD relative to the assay- and run-specific cut-off values ($OD_{\text{sample}}/OD_{\text{cut-off}}$), where $OD_{\text{cut-off}} = 1.1 \times OD_{\text{cal}}$ for both Euroimmun ELISAs, $OD_{\text{cut-off}} = (1.1 + 0.18) \times OD_{\text{NC}}$ for EDI IgG and $OD_{\text{cut-off}} = (1.1 + 0.10) \times OD_{\text{NC}}$ for EDI IgM, where OD_{cal} and OD_{NC} are calibration respectively average negative control values as described by the manufacturers. Note that fold changes are not comparable between Euroimmun and EDI ELISA

test kits because the assays show large differences in dynamic range and saturation.
Detailed calculation can be found in the supplementary methods.

2.4. Statistical analysis

Patient data and results of POCTs were originally stored in the REDCap database system of the Canton Hospital Basel-Landschaft. Results from ELISA tests were entered into Excel worksheets. All data were preprocessed and a common database created using in-house scripts in R [18]. Statistical analysis and creation of figures and tables was carried out using R; binomial confidence intervals are 95%-Clopper-Pearson intervals calculated using `exactci()` from package `PropCIs` [19]. A refresher for the calculation of specificity and sensitivity calculation can be found in the supplementary methods.

2.5. Role of the funding source

The sponsor had no role in study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the paper for publication.

3. Results

3.1. Study design & cohorts

The goal of our study design was to collect a representative cohort of COVID-19 disease manifestation during the first wave of COVID-19 in the canton Basel-Landschaft, Switzerland. During the initial phase of the pandemic, only people in risk groups showing symptoms were tested; later, testing was extended to all people showing symptoms and 5311 people had been tested in the canton at the beginning of study recruitment, with 802 (15.1%) positive and 4509 (84.9%) negative PCR test results. The cases were mostly observed close to or in areas with a high frequency of commuting to the city of Basel, but the ratio of positive tests showed no apparent bias for or against rural communities.

All RT-PCR-tested individuals were eligible for participation except when they were <18 years of age, had a severely compromised immune system, were hospitalized at the time of sample collection, or were deceased. From these, 349 positive individuals committed to participating in the study, and 111 negative individuals were randomly selected. We aimed for sufficient sample size for two positive cohorts: an 'acute' cohort with diagnosed COVID-19 up to 12 days before study entry, and a 'convalescent' cohort with more than 12 days between positive diagnosis and study entry.

152 Individuals were continuously recruited during a 2 week window from 11. April
 153 2020 to 22. April 2020 and visited the 'Abklärungsstation COVID-19' in Münchenstein,
 154 Switzerland. The medical history and the status were recorded in a doctors interview,
 155 the vital parameters were acquired, and saliva and blood samples were collected. All
 156 participants of the positive cohort were guided through the building, while the negative
 157 cohort was examined in a make-shift field hospital erected next to the building to mini-
 158 mize the danger of infection with COVID-19. Participant characteristics are summarized
 159 in Table 1.

Cohort	PCR pos, ≤ 7 d (N = 31)	PCR pos, > 7 d & ≤ 12 d (N = 46)	PCR pos, > 12 d (N = 272)	PCR neg, > 5 d (N = 111)
Sex				
female	17 (55%)	25 (54%)	130 (48%)	63 (57%)
male	14 (45%)	21 (46%)	142 (52%)	48 (43%)
Age				
years, median (range)	45 (21-80)	51 (20-80)	51.5 (17-93)	48 (19-87)
Weight				
kg, median (range)	73 (51-110)	72 (40-109)	76 (49-135)	73 (47-130)
Height				
cm, median (range)	173.5 (157-187)	172 (150-191)	173 (72-198)	172 (149-195)
SpO2				
%, median (range)	98 (93-99)	98 (88-99)	98 (85-99)	98 (95-99)
Total days ill				
0–5 days	6 (19%)	1 (2%)	28 (10%)	—
5–10 days	15 (48%)	23 (50%)	146 (54%)	—
10–14 days	10 (32%)	22 (48%)	98 (36%)	—

Table 1: Characteristics of patients included in the study.

160 Distribution of ages and gender for the positive cohort are similar to the age and gen-
 161 der structure of the canton, except for the age between 40–65 which are over-represented
 162 and >80 which are under-represented (Table 2 and Supplementary Figure 1). From the
 163 349 positive participants, 35 (10%) were bedridden during the acute disease, 62 (18%)
 164 required help for their daily activities, while 244 (72%) had no restrictions. Similar dis-
 165 tributions are reported elsewhere. All age groups were affected equally, however severe
 166 cases were more pronounced in the older population. Increasing disease severity cor-
 167 related with the experienced symptoms; bedridden cases suffered approximately 10 or
 168 more days, cases requiring help ~10 days, and the oligosymptomatic cases between 5 to
 169 15 days.

	Age groups						
	15–19*	20–29	30–39	40–49	50–64	65–79	80+
Overall	5 (1.1%)	55 (12%)	64 (13.9%)	99 (21.5%)	159 (34.6%)	68 (14.8%)	10 (2.2%)
Severity of illness							
Not ill	1 (20%)	13 (24%)	23 (36%)	24 (24%)	29 (18%)	18 (26%)	3 (30%)
No restrictions	4 (80%)	36 (65%)	34 (53%)	53 (54%)	91 (57%)	28 (41%)	4 (40%)
Help needed	0 (0%)	6 (11%)	6 (9%)	18 (18%)	22 (14%)	9 (13%)	1 (10%)
Bedridden	0 (0%)	0 (0%)	1 (2%)	4 (4%)	17 (11%)	13 (19%)	2 (20%)
Total days ill							
0–5 days	0 (0%)	7 (17%)	5 (12%)	7 (9%)	11 (8%)	5 (10%)	0 (0%)
5–10 days	3 (75%)	19 (45%)	24 (59%)	39 (52%)	72 (55%)	24 (48%)	3 (43%)
10–15 days	1 (25%)	16 (38%)	12 (29%)	29 (39%)	47 (36%)	21 (42%)	4 (57%)
Baselland (2019)	13924 (5.6%)	30882 (12.4%)	35666 (14.3%)	39190 (15.7%)	65017 (26.1%)	45175 (18.1%)	19054 (7.7%)

Table 2: Age structure of study cohort stratified by severity and by duration of symptoms. Last row shows distribution of ages 15+ in canton of Basel-Land in 2019 for reference. *Note that our study cohort does not include minors with less than 18 years of age.

We use two negative cohorts; (i) samples from 150 2016/17 influenza period blood donors, and (ii) our negative cohort. These cohorts should strengthen the specificity calculations, but also help to address cross-reactivity to viruses currently in circulation. However, the PCR test is prone to false negatives, and we therefore expect to find a small number of incorrectly diagnosed individuals. In line with the reported false negative rate of 15–25% [20, 21], we identified four individuals with negative PCR results but seroconverted in both Euroimmun IgG and IgA and Epitope Diagnostics (EDI) IgG. We consider these four individuals as false negative PCR results and removed them from the dataset. All results are only influenced marginally by this step.

3.2. Performance characteristics of ELISA tests

3.2.1. Sensitivity & specificity

We performed the EDI and Euroimmun assays according to the manufacturer’s instructions on all samples. The obtained data were normalized (see Material and Methods section) to make results comparable between experiments. The reported fold-changes are defined as the ratio between measured OD and the classification cut-off OD specified by the manufacturer (Figure 1 & Supplementary Figure 2). Positive/negative classification was performed according to manufacturer’s instructions, and the assay performance was calculated therefrom.

We used a patient’s assignment to the PCR-positive or PCR-negative cohort together with the corresponding ELISA test result for calculating performance characteristics for all four assays. The values considering all data are shown in the top of Table 3. We find specificities of the IgG-based assays of about 98%-99%, while IgA shows considerably lower and IgM considerably higher specificity overall. To determine potential cross-reactivity of the assays, we separately calculated the specificity from the 150 samples of the 2016 blood donor cohort (Table 3 (bottom)). Nevertheless, the histogram of all assays and data show overlap between the cohorts (Supplementary Figure 3).




Figure 1: **Overview on ELISA results.** Epitope Diagnostics (EDI) and Euroimmun assays were performed with serum from 607 individuals. The negative cohort consists of 150 serum samples collected during the 2016/17 influenza period and 110 serum samples from PCR-negative individuals from 2020. Positive cases are stratified by days post symptoms onset (left) and additionally stratified by disease severity (right). Fold changes are defined as the ratio between measured OD and the classification cut-off OD specified by the manufacturer. Grey area indicates the range where serum samples are classified as uncertain; samples above (below) this area are classified as positive (negative).

	EDI				Euroimmun		
	Serum		Plasma		Serum		
	IgM	IgG	IgM	IgG	IgA	IgG	IgG 1.5×
TP	161	287	176	280	304	291	272
FP	3	6	11	12	22	2	0
TN	257 (2)	254 (7)	100 (11)	99 (13)	238 (12)	258 (2)	260 (0)
FN	184 (35)	58 (16)	161 (36)	57 (14)	41 (15)	54 (12)	73 (0)
Se [CI], %	46.7 [41.3, 52.1]	83.2 [78.8, 87]	52.2 [46.7, 57.7]	83.1 [78.6, 86.9]	88.1 [84.2, 91.3]	84.3 [80.1, 88]	78.8 [74.1, 83]
Sp [CI], %	98.8 [96.7, 99.8]	97.7 [95, 99.1]	90.1 [83, 94.9]	89.2 [81.9, 94.3]	91.5 [87.5, 94.6]	99.2 [97.2, 99.9]	100 [98.6, 100]
2016 blood donors							
TN	150 (0)	147 (3)	—	—	136 (7)	150 (2)	150 (0)
FP	0	3	—	—	14	0	0
Sp [CI], %	100 [97.6, 100]	98 [94.3, 99.6]	—	—	90.7 [84.8, 94.8]	100 [97.6, 100]	100 [97.6, 100]

Table 3: Top: Number true positive (TP), false positive (FP), true negative (TN), false negative (FN), sensitivity (Se) and specificity (Sp) for Epitope Diagnostics (EDI) serum and plasma samples and Euroimmun ELISA serum samples for all cohorts. All samples with uncertain result were considered negative for the analysis (number of uncertain samples shown in brackets). Column IgG 1.5× for Euroimmun corresponds to using a threshold of 1.5 instead of 1.1 for the OD-ratio. Bottom: specificity based on serum samples of negative 2016 blood donor cohort only.

196 The IgG- and IgA-based assays show overall sensitivities above 87%, while the sen-
 197 sitivity of IgM is extremely low at slightly above 50%. However, the different types of
 198 antibodies act at different stages of the immune response. We therefore stratified the
 199 calculation of assay sensitivities by days after onset of symptoms into three categories:
 200 14 days or less, 15 to 20 days, and 21 days or more (Table 4 & Supplementary Fig-
 201 ure 4). Sensitivities increase with days after onset of symptoms for both IgG assays from
 202 about 50% to 95%. The sensitivity of the IgM assay remains low for all strata, while
 203 IgA already shows substantially higher sensitivities than all other assays for less than
 204 14 days after onset of symptoms. Specifically, sensitivity is low for the EDI Diagnostics
 205 IgM assay, reaching a maximum of 64% for two to three weeks after onset of symptoms.
 206 Both IgG assays show overall sensitivities below 90%, but sensitivities increase to 95% or
 207 higher three weeks after onset of symptoms. The Euroimmun IgA sensitivity is highest
 208 among the four assays for less than two weeks after onset of symptoms with 82% and
 209 also reaches about 95% after three weeks or more after onset of symptoms.

EDI ELISA						
	IgM			IgG		
	≤ 14 days	15–20 days	≥ 21 days	≤ 14 days	15–20 days	≥ 21 days
TP	20	32	109	29	44	214
FN	34 (5)	20 (4)	130 (26)	25 (2)	8 (1)	25 (13)
Se [CI], %	37 [24.3, 51.3]	61.5 [47, 74.7]	45.6 [39.2, 52.2]	53.7 [39.6, 67.4]	84.6 [71.9, 93.1]	89.5 [84.9, 93.1]
Euroimmun ELISA						
	IgA			IgG		
	≤ 14 days	15–20 days	≥ 21 days	≤ 14 days	15–20 days	≥ 21 days
TP	40	46	218	23	42	226
FN	14 (5)	6 (1)	21 (9)	31 (3)	10 (4)	13 (5)
Se [CI], %	74.1 [60.3, 85]	88.5 [76.6, 95.6]	91.2 [86.9, 94.5]	42.6 [29.2, 56.8]	80.8 [67.5, 90.4]	94.6 [90.9, 97.1]

Table 4: Sensitivity of EDI (top) and Euroimmun (bottom) ELISA stratified by days after onset of symptoms. All samples with uncertain result were considered negative for the analysis (number of uncertain samples shown in brackets).

210 We performed the same analysis stratified by three levels of disease severity—‘no
 211 restriction’, ‘help needed’, and ‘bedridden’—and combined these levels with two levels
 212 for days after onset of symptoms: short (≤ 21 days) or long (> 21 days). The resulting
 213 sensitivities and specificities and their 95% confidence intervals are given in Table 5. As
 214 expected, sensitivities also increase with severity of symptoms for both less and more
 215 than three weeks after onset of symptoms, but sample sizes are comparatively small for
 216 shorter time and higher severity. Notably, the IgG response is detectable in all samples
 217 of the ‘bedridden’ cohort > 21 days, and is then comparable to the manufacturer’s
 218 characterisation on this subset.

EDI IgM						
	Bedridden		Help needed		No restrictions	
	≤ 21d	> 21d	≤ 21d	> 21d	≤ 21d	> 21d
TP	7	20	15	23	36	60
FN	2 (2)	6 (3)	4 (0)	20 (6)	54 (8)	98 (16)
Se [CI], %	77.8 [40, 97.2]	76.9 [56.4, 91]	78.9 [54.4, 93.9]	53.5 [37.7, 68.8]	40 [29.8, 50.9]	38 [30.4, 46]
EDI IgG						
	Bedridden		Help needed		No restrictions	
	≤ 21d	> 21d	≤ 21d	> 21d	≤ 21d	> 21d
TP	8	25	17	39	58	140
FN	1 (0)	1 (1)	2 (0)	4 (2)	32 (4)	18 (9)
Se [CI], %	88.9 [51.8, 99.7]	96.2 [80.4, 99.9]	89.5 [66.9, 98.7]	90.7 [77.9, 97.4]	64.4 [53.7, 74.3]	88.6 [82.6, 93.1]
Euroimmun IgA						
	Bedridden		Help needed		No restrictions	
	≤ 21d	> 21d	≤ 21d	> 21d	≤ 21d	> 21d
TP	9	25	18	40	71	141
FN	0 (0)	1 (0)	1 (0)	3 (2)	19 (6)	17 (7)
Se [CI], %	100 [66.4, 100]	96.2 [80.4, 99.9]	94.7 [74, 99.9]	93 [80.9, 98.5]	78.9 [69, 86.8]	89.2 [83.3, 93.6]
Euroimmun IgG						
	Bedridden		Help needed		No restrictions	
	≤ 21d	> 21d	≤ 21d	> 21d	≤ 21d	> 21d
TP	7	25	16	42	53	148
FN	2 (0)	1 (1)	3 (0)	1 (0)	37 (7)	10 (4)
Se [CI], %	77.8 [40, 97.2]	96.2 [80.4, 99.9]	84.2 [60.4, 96.6]	97.7 [87.7, 99.9]	58.9 [48, 69.2]	93.7 [88.7, 96.9]

Table 5: Sensitivities stratified by severity of illness. All samples with uncertain result were considered negative for the analysis (number of uncertain samples shown in brackets).

219 3.2.2. Reproducibility and linearity

220 Intra-assay variability was determined by calculating the mean, standard deviation,
221 and coefficient of variation of the measured OD ratios based in 5 replicate measurements
222 of 8 samples with values ranging from at or below the threshold limit to about the 75%
223 quartile in the two IgG and IgA assays (Supplementary Table 5 & Supplementary Fig-
224 ure 6). In general, reproducibility was high with coefficients of variation of 5% or smaller
225 in samples well above the threshold. This variation increased to $\sim 10\%$ at or below the
226 threshold. It is trivial but important to state that, at the threshold, this variability can
227 lead to different classification in each repetition. Last, different samples show different
228 variabilities in the two IgG assays, possibly indicating the difference between the binding
229 epitope and assay manufacturing.

230 We investigated the assay linearity using two-fold serially diluted serum samples from
231 5 individuals with high OD values for IgG (Supplementary Figure 11). Both Euroim-
232 mun assays showed a good linearity over a dilution range of 64-fold (2^6 dilutions), while
233 the IgG Epitope Diagnostics (EDI) assay is linear only in a 16-fold (2^4) dilution range.
234 Additionally, both IgG assays show good agreement along the dilutions (Supplementary
235 Figure 10), suggesting that—after normalization and scaling—the IgG assays give com-
236 parable quantitative results. No data of sufficient quality was acquired for a discussion
237 of the IgM assay (Supplementary Figure 11). Additionally, we found that the IgG, but
238 not the IgM, assay from EDI is sensitive to haemolysis (Supplementary Figure 12).

239 3.3. Kinetics of seroconversion

240 Our positive cohort can give insight into the kinetics of seroconversion at the pop-
241 ulation level for different antibody types and epitopes and a broad range of disease
242 manifestations. The two ELISA tests employ different epitopes: the EDI test recognizes
243 the SARS-CoV-2 nucleocapsidprotein and uses IgG and IgA while the Euroimmun test
244 recognizes the S1 portion of the spike protein using IgG and IgM.

245 For all antibody types, the strength of the response over time correlated with severity
246 of the symptoms (Figure 2A). We only measured a well discernible IgM response in the
247 "bedridden" group and a slight response in the "help needed" group, while it was largely
248 absent from the "no restriction" group. On the other hand, the IgA and IgG response
249 is measurable in most samples. The average response is higher when "bedridden", while
250 similar antibody response levels are observed for "no restriction" and "help needed".

251 In most viral host responses, the earliest measurable response is IgM followed by IgG

and IgA. Surprisingly, but in line with other reports for SARS-CoV-2 [10, 11] as well as observations for SARS and MERS, all three antibody types reacted within a similar timeframe. The earliest detection, within a week of symptom onset, was for IgA, followed by IgM and IgG both detected from week 2. IgM then peaked 2–3 weeks and IgA 3–4 weeks post symptom onset, while no decline for IgG was measured. The temporal order of these peaks can be expected based on the half-life time of the different antibody types in the blood.

These observations are further substantiated from observing the responses on the level of the individuals. Most interestingly, we find a robust IgG response against the NCP early on, whereas the response to the spike protein seems to be more prevalent at later time points (Figure 2A). However, neither IgG response is significantly different depending on the severity of the disease. The IgA response against the spike protein is produced rapidly in the absence of an IgG response but subsides at later time points when the IgG response becomes dominant.

4. Discussion

Here, we describe the collection and initial characterisation of a blood bank from the affected population of the canton Basel-Landschaft, Switzerland. Almost 50% of the people fallen ill with COVID-19 participated in this study and the biobank is therefore exemplary for an outbreak in a western European community. In particular, the COVID-19 severity and symptoms in the biobank samples closely follow the reported distributions elsewhere. We might have slightly biased our cohorts toward less severe cases, by excluding samples from actively hospitalized or deceased patients. Since only 11 cases remained in the hospital at the time of recruitment, this bias is likely small. Overall, we consider the largely representative sample a strength of our biobank, as it allows us to estimate the kinetics of seroconversion and assay performance characteristics on samples closely resembling those expected in population-wide studies for sero-prevalence.

We find that both specificity and sensitivity are below the manufacturer’s specifications for all four tests, and observe similar sensitivities only for our ‘bedridden’ group. This indicates that characterizations by the manufacturers are likely based on ‘severe’ cohorts, which limits their applicability and impairs planning of sero-prevalence studies. We also find that the IgA and IgG assays allow for quantification within a relatively narrow range: the linear range of the Euroimmun assay covers approximately a 64-fold




Figure 2: A: Log₂-fold changes in ELISA signal for each assay by time after symptoms onset and by disease severity. Data was fitted using smoothing splines to visualize trends (figure shows fits and 95% confidence intervals). Grey area indicates the range where serum samples are classified as uncertain; samples above (below) this area are classified as positive (negative). B: Scatterplots comparing log₂-fold changes in IgA vs IgG measured by Euroimmun ELISA (left), IgG measured by Euroimmun ELISA vs IgG measured by Epitepe Diagnostics (EDI) ELISA (center), and Euroimmun IgA vs EDI IgG (right) by disease severity. C: As in B but with days after onset of symptoms. Fold-changes are defined as the ratio between measured OD and the classification cut-off OD specified by the manufacturer.

dilution range and the EDI assay a 16-fold dilution range. When calculating sensitivities and specificities with our cohort, the IgA test shows the highest sensitivity, followed by the two IgG assays. The poor sensitivity of the IgM test is either due to the absence of a dedicated IgM response [22] in line with previous reports or poor test performance. The highest specificity is achieved with the Euroimmun IgG test. The specificity could be further boosted by a higher cut-off as previously reported, however accompanied by a concurrent drop in sensitivity (Supplementary Tables 14, 15, 16).

The average strength of the antibody response, as measured by the ratios, correlates with the severity of the disease at each time point. However, the differences vanish the longer post-symptoms onset the individuals are, and the measured amount in an individual is not predictive for the severity of the disease. Surprisingly, but similar to earlier reports, we measured that the temporal order of the response is shifted. IgA is measured within 1–2 weeks after symptoms onset, followed by the IgG response at week 2–3, while a clear IgM response is absent. Especially at earlier time points, the IgA response is stronger than the IgG response as measured using the S1 spike protein epitope in the Euroimmun assay. To fully understand what the obtained values reflect and how they correlate with diseases and protection from disease, further analyses are planned including measuring the strength to neutralize pseudo-typed viral particles and analysing the individual antibodies by sequencing the PBMCs. However, our current data help to understand the limitations of the current antibody tests on the market and serve as the basis to interpret ongoing studies on other lab assay characterization, POCT performances and PBMC sequencing.

Acknowledgement

This study was sponsored by Jürg Sommer, head of the "Amt für Gesundheit", and the logistics of the sample collection were provided by the crisis staff and the civil protection service of the canton Basel-Landschaft. FR is funded by the NCCR 'Molecular Systems Engineering'. Funding for JD from the two Cantons of Basel through project grant PMB-01-17 granted by the ETH Zurich is acknowledged.

Funding for TR, DP, BN Funding for MS

313 References

- 314 [1] A. T. Huang, B. Garcia-Carreras, M. D. Hitchings, B. Yang, L. Katzelnick, S. M.
315 Rattigan, B. Borgert, C. Moreno, B. D. Solomon, I. Rodriguez-Barraquer, et al.,
316 A systematic review of antibody mediated immunity to coronaviruses: antibody
317 kinetics, correlates of protection, and association of antibody responses with severity
318 of disease, medRxiv (2020).
- 319 [2] J. AJ, A. MJ, et al., Performance of six SARS-CoV-2 immunoassays in comparison
320 with microneutralisation, Journal of clinical virology: the official publication of the
321 Pan American Society for Clinical Virology 129 (2020) 104512.
- 322 [3] F. Schmidt, Y. Weisblum, F. Muecksch, H.-H. Hoffmann, E. Michailidis, J. C.
323 Lorenzi, P. Mendoza, M. Rutkowska, E. Bednarski, C. Gaebler, et al., Measur-
324 ing SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric
325 viruses, bioRxiv (2020).
- 326 [4] F. Amanat, D. Stadlbauer, S. Strohmeier, T. H. Nguyen, V. Chromikova, M. McMa-
327 hon, K. Jiang, G. A. Arunkumar, D. Jurczynszak, J. Polanco, et al., A serological
328 assay to detect SARS-CoV-2 seroconversion in humans, Nature medicine (2020)
329 1–4.
- 330 [5] Y. Shi, Y. Yi, P. Li, T. Kuang, L. Li, M. Dong, Q. Ma, C. Cao, Diagnosis of severe
331 acute respiratory syndrome (SARS) by detection of SARS coronavirus nucleocapsid
332 antibodies in an antigen-capturing enzyme-linked immunosorbent assay, Journal of
333 clinical microbiology 41 (2003) 5781–5782.
- 334 [6] P. D. Burbelo, F. X. Riedo, C. Morishima, S. Rawlings, D. Smith, S. Das, J. R.
335 Strich, D. S. Chertow, R. T. Davey Jr, J. I. Cohen, Sensitivity in detection of
336 antibodies to nucleocapsid and spike proteins of severe acute respiratory syndrome
337 coronavirus 2 in patients with coronavirus disease 2019, The Journal of infectious
338 diseases (2020).
- 339 [7] F. Wu, A. Wang, M. Liu, Q. Wang, J. Chen, S. Xia, Y. Ling, Y. Zhang, J. Xun,
340 L. Lu, et al., Neutralizing antibody responses to SARS-CoV-2 in a COVID-19
341 recovered patient cohort and their implications (2020).

- 342 [8] T. F. Rogers, F. Zhao, D. Huang, N. Beutler, A. Burns, W.-t. He, O. Limbo,
343 C. Smith, G. Song, J. Woehl, et al., Isolation of potent SARS-CoV-2 neutralizing
344 antibodies and protection from disease in a small animal model, *Science* (2020).
- 345 [9] N. M. Okba, M. A. Müller, W. Li, C. Wang, C. H. GeurtsvanKessel, V. M. Corman,
346 M. M. Lamers, R. S. Sikkema, E. de Bruin, F. D. Chandler, et al., Severe acute res-
347 piratory syndrome coronavirus 2-specific antibody responses in coronavirus disease
348 2019 patients., *Emerging infectious diseases* 26 (2020).
- 349 [10] B. Sun, Y. Feng, X. Mo, P. Zheng, Q. Wang, P. Li, P. Peng, X. Liu, Z. Chen,
350 H. Huang, et al., Kinetics of SARS-CoV-2 specific IgM and IgG responses in COVID-
351 19 patients, *Emerging Microbes & Infections* (2020) 1–36.
- 352 [11] Q.-X. Long, B.-Z. Liu, H.-J. Deng, G.-C. Wu, K. Deng, Y.-K. Chen, P. Liao, J.-F.
353 Qiu, Y. Lin, X.-F. Cai, et al., Antibody responses to SARS-CoV-2 in patients with
354 COVID-19, *Nature medicine* (2020) 1–4.
- 355 [12] L. Shen, C. Wang, J. Zhao, X. Tang, Y. Shen, M. Lu, Z. Ding, C. Huang, J. Zhang,
356 S. Li, et al., Delayed specific IgM antibody responses observed among COVID-19
357 patients with severe progression, *Emerging Microbes & Infections* 9 (2020) 1096–
358 1101.
- 359 [13] M. S. Suthar, M. G. Zimmerman, R. C. Kauffman, G. Mantus, S. L. Linderman,
360 W. H. Hudson, A. Vanderheiden, L. Nyhoff, C. W. Davis, S. Adekunle, et al., Rapid
361 generation of neutralizing antibody responses in COVID-19 patients, *Cell Reports*
362 *Medicine* (2020).
- 363 [14] R. Wölfel, V. M. Corman, W. Guggemos, M. Seilmaier, S. Zange, M. A. Müller,
364 D. Niemeyer, T. C. Jones, P. Vollmar, C. Rothe, et al., Virological assessment of
365 hospitalized patients with COVID-2019, *Nature* 581 (2020) 465–469.
- 366 [15] J. Lathrop, FDA, Analytical validation and points for discussion, 2016.
- 367 [16] S. Ubol, S. B. Halstead, How innate immune mechanisms contribute to antibody-
368 enhanced viral infections, *Clinical and Vaccine Immunology* 17 (2010) 1829–1835.
- 369 [17] J. Xie, C. Ding, J. Li, Y. Wang, H. Guo, Z. Lu, J. Wang, C. Zheng, T. Jin, Y. Gao,
370 et al., Characteristics of patients with coronavirus disease (COVID-19) confirmed
371 using an IgM-IgG antibody test, *Journal of medical virology* (2020).

- 372 [18] R Core Team, R: A Language and Environment for Statistical Computing, R Foun-
373 dation for Statistical Computing, Vienna, Austria, 2019.
- 374 [19] R. Scherer, PropCIs: Various Confidence Interval Methods for Proportions, 2018. R
375 package version 0.3-0.
- 376 [20] L. M. Kucirka, S. A. Lauer, O. Laeyendecker, D. Boon, J. Lessler, Variation in false-
377 negative rate of reverse transcriptase polymerase chain reaction-based SARS-CoV-2
378 tests by time since exposure, *Annals of Internal Medicine* (2020).
- 379 [21] A. T. Xiao, Y. X. Tong, S. Zhang, False-negative of RT-PCR and prolonged nucleic
380 acid conversion in COVID-19: rather than recurrence, *Journal of medical virology*
381 (2020).
- 382 [22] H. Ma, W. Zeng, H. He, D. Zhao, D. Jiang, P. Zhou, L. Cheng, Y. Li, X. Ma,
383 T. Jin, Serum IgA, IgM, and IgG responses in COVID-19, *Cellular & Molecular*
384 *Immunology* (2020) 1–3.